We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.42%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.07B
AUM Growth
+$166M
Cap. Flow
+$47.2M
Cap. Flow %
4.41%
Top 10 Hldgs %
29.4%
Holding
105
New
13
Increased
43
Reduced
32
Closed
11

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$17.2M
2
DOCS icon
Doximity
DOCS
+$13.3M
3
AMGN icon
Amgen
AMGN
+$11.4M
4
NUVL
Nuvalent
NUVL
+$10.9M
5
VERA icon
Vera Therapeutics
VERA
+$10.3M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$19M
2
CAH icon
Cardinal Health
CAH
+$14.8M
3
ABT icon
Abbott
ABT
+$13.2M
4
CYTK icon
Cytokinetics
CYTK
+$13.1M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
1
Regeneron Pharmaceuticals
REGN
$78.5B
$47.4M 4.43%
61,400
+25,300
+70% +$17.2M
LLY icon
2
Eli Lilly
LLY
$1.02T
$45.4M 4.24%
42,220
-11,200
-21% -$10.7M
BSX icon
3
Boston Scientific
BSX
$69.5B
$41.1M 3.84%
431,207
-6,793
-2% -$666K
MDT icon
4
Medtronic
MDT
$109B
$28.4M 2.66%
296,000
+91,000
+44% +$8.84M
ISRG icon
5
Intuitive Surgical
ISRG
$127B
$27.2M 2.54%
48,000
-500
-1% -$266K
COO icon
6
Cooper Companies
COO
$14.1B
$26.8M 2.51%
327,500
+90,500
+38% +$6.77M
CVS icon
7
CVS Health
CVS
$133B
$26.6M 2.49%
335,500
+58,138
+21% +$4.58M
ABBV icon
8
AbbVie
ABBV
$443B
$25.3M 2.36%
110,575
-19,800
-15% -$4.51M
GKOS icon
9
Glaukos
GKOS
$9.83B
$23.7M 2.22%
210,000
-20,000
-9% -$1.91M
DHR icon
10
Danaher
DHR
$137B
$22.7M 2.12%
99,052
-35,400
-26% -$7.78M
COR icon
11
Cencora
COR
$60.6B
$21.4M 2%
63,375
+1,000
+2% +$341K
VERA icon
12
Vera Therapeutics
VERA
$2.3B
$21.3M 1.99%
420,000
+290,000
+223% +$10.3M
MCK icon
13
McKesson
MCK
$100B
$21M 1.96%
25,600
-1,000
-4% -$816K
AXSM icon
14
Axsome Therapeutics
AXSM
$11.2B
$21M 1.96%
114,800
-58,000
-34% -$8.1M
ALHC icon
15
Alignment Healthcare
ALHC
$3.08B
$19.9M 1.86%
1,009,450
-469,834
-32% -$8.44M
INSM icon
16
Insmed
INSM
$21.4B
$19.8M 1.85%
113,585
-18,300
-14% -$3.34M
TMO icon
17
Thermo Fisher Scientific
TMO
$213B
$19.5M 1.82%
33,640
+3,600
+12% +$2.04M
PRCT icon
18
Procept Biorobotics
PRCT
$1.06B
$19.2M 1.8%
611,000
+221,000
+57% +$7.33M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$27.5B
$18.2M 1.7%
45,675
+13,800
+43% +$6.11M
UNH icon
20
UnitedHealth
UNH
$376B
$18.1M 1.69%
54,900
-7,630
-12% -$2.59M
NBIX icon
21
Neurocrine Biosciences
NBIX
$16.8B
$17.8M 1.66%
125,491
+10,774
+9% +$1.56M
PODD icon
22
Insulet
PODD
$11.5B
$17.3M 1.62%
61,000
+3,000
+5% +$938K
DOCS icon
23
Doximity
DOCS
$3.76B
$16.5M 1.54%
372,750
+236,750
+174% +$13.3M
EW icon
24
Edwards Lifesciences
EW
$49.6B
$16.5M 1.54%
193,500
+38,500
+25% +$3.16M
NUVL
25
DELISTED
Nuvalent
NUVL
$16.4M 1.54%
163,350
+110,850
+211% +$10.9M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Rhenman & Partners Asset Management held 105 positions worth $1.07B, up 18% from $904M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $47.2M of net new capital in Q4 2025, opening 13 new positions and adding to 43 existing holdings. Its largest new stake was Amgen: 36,000 shares worth $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $13.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2025 buy was Amgen: 36,000 shares worth $11.8M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q4 2025, an estimated $17.2M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $13.1M.
  • Rhenman & Partners Asset Management fully exited Exact Sciences in Q4 2025, selling an estimated $19M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.07B portfolio in Q4 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q4 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.07B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.